Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | LTK | P29376 | 2/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18264175 | 0.94 | KDM1A (0.52) | EGFRNPC1TP53PKMALOX15 | |
| SCHEMBL18264156 | 0.91 | NPY5R (0.50) | NPC1TP53MAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL18264174 | 0.91 | GAA (0.52) | TP53ALOX15TSHRMAPK1TAAR1 | |
| SCHEMBL18264161 | 0.91 | ABCG2 (0.51) | EGFRNPC1TP53ALOX15TSHR | |
| SCHEMBL18264159 | 0.91 | MAPT (0.52) | EGFRNPC1TP53RAB9ATAAR1 | |
| SCHEMBL18264154 | 0.88 | ABCG2 (0.53) | EGFRNPC1RAB9AKDRABCG2 | |
| SCHEMBL18264168 | 0.88 | MEN1 (0.52) | EGFRTP53TSHRSMN1; SMN2TAAR1 | |
| SCHEMBL21840862 | 0.88 | SLC2A1 (0.55) | EGFRTP53SMN1; SMN2KDRABCG2 | |
| SCHEMBL18264134 | 0.88 | NPY5R (0.53) | NPC1TP53MAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL18264164 | 0.88 | ABCG2 (0.52) | EGFRRAB9AKDM1AKDRABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3302060-B1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE | UNIV KAOHSIUNG MEDICAL (TW) | 2020-02-12 | — | — | EP | claimed |
| US-20180214426-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2018-08-02 | — | — | US | claimed |
| EP-3302060-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE | Kaohsiung Medical University (TW) | 2018-04-11 | — | — | EP | claimed |
| WO-2016191576-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF β-GLUCURONIDASE | DCB-USA LLC (US) | 2016-12-01 | — | — | WO | claimed |
| CN-111514144-B | Pyrazolo [4,3-c ] quinoline derivatives having inhibitory activity on bacterial glucuronidase | 高雄医学大学 | 2021-10-26 | — | — | CN | disclosed |
| EP-3662751-B1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF B-GLUCURONIDASE | UNIV KAOHSIUNG MEDICAL (TW) | 2021-10-13 | — | — | EP | disclosed |
| US-11135206-B2 | Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2021-10-05 | — | — | US | disclosed |
| US-11135206-B2 | Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2021-10-05 | — | — | US | disclosed |
| CN-107708419-B | Pyrazolo [4,3-c ] quinoline derivatives having inhibitory activity on bacterial glucuronidase | 高雄医学大学 | 2021-08-27 | — | — | CN | disclosed |
| US-11052072-B2 | Pyrazolo[4,3-C] quinoline derivatives for inhibition of β-glucuronidase | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2021-07-06 | — | — | US | disclosed |
| US-11052072-B2 | Pyrazolo[4,3-C] quinoline derivatives for inhibition of β-glucuronidase | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2021-07-06 | — | — | US | disclosed |
| CN-111514144-A | Pyrazolo [4,3-c ] quinoline derivatives having inhibitory activity on bacterial glucuronidase | 高雄医学大学 | 2020-08-11 | — | — | CN | disclosed |
| US-20200113878-A1 | PYRAZOLO[4,3-C]Quinoline Derivatives For Inhibition Of Beta-Glucuronidase | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2020-04-16 | — | — | US | disclosed |
| EP-3302060-B1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE | UNIV KAOHSIUNG MEDICAL (TW) | 2020-02-12 | — | — | EP | disclosed |
| EP-3302060-B1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE | UNIV KAOHSIUNG MEDICAL (TW) | 2020-02-12 | — | — | EP | disclosed |
| US-20180214426-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2018-08-02 | — | — | US | disclosed |
| US-20180214426-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2018-08-02 | — | — | US | disclosed |
| US-20180214426-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2018-08-02 | — | — | US | disclosed |
| EP-3302060-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE | Kaohsiung Medical University (TW) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016191576-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF β-GLUCURONIDASE | DCB-USA LLC (US) | 2016-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214426-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE | UGT1A3, UGT1A1, GUSB | EGFR 2582/4885NPC1 2855/4885TP53 321/4885 |
| US-20200113878-A1 | PYRAZOLO[4,3-C]Quinoline Derivatives For Inhibition Of Beta-Glucuronidase | UGT1A3, UGT1A1, GUSB | EGFR 2582/4885NPC1 2855/4885TP53 321/4885 |
| US-11052072-B2 | Pyrazolo[4,3-C] quinoline derivatives for inhibition of β-glucuronidase | UGT1A3, UGT1A1, DPP3 | EGFR 2371/4885NPC1 2883/4885TP53 295/4885 |
| US-11135206-B2 | Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase | UGT1A3, UGT1A1, DPP3 | EGFR 2371/4885NPC1 2883/4885TP53 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.